Renal Transplantation and Raltegravir in HIV-Infected Patients (ANRS153TREVE)
This study is ongoing, but not recruiting participants.
Sponsor:
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
ClinicalTrials.gov Identifier:
NCT01453192
First received: October 3, 2011
Last updated: October 28, 2014
Last verified: October 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this study is to evaluate the incidence of acute renal graft rejection 6 months after transplantation in HIV-infected patients under three antiretroviral drugs regimen including Raltegravir.
| Condition | Intervention | Phase |
|---|---|---|
|
HIV-1 Infection Chronic Renal Insufficiency |
Drug: Raltegravir |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | National, Multicenter, Phase III Prospective Trial About Clinical and Immunological Follow-up After Renal Transplantation in HIV-1 Infected Patients With End Stage Chronic Renal Insufficiency |
Resource links provided by NLM:
Further study details as provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):
Primary Outcome Measures:
- Incidence of acute clinical renal graft rejection [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]Incidence of acute clinical renal graft rejection defined by 20% increase of serum creatinine, associated to histological features (Banff classification) 6 months after renal transplantation
Secondary Outcome Measures:
- Incidence of acute clinical and subclinical renal graft rejection [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]Incidence of acute clinical and subclinical renal graft rejection up to 1 year after renal transplantation defined only by renal histology (without creatinine modification). Histology is performed on routine renal graft biopsy 3 months and 1 year after transplantation.
- One year graft survival [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]One year graft survival, compared to non HIV-infected transplanted patients, using data provided by French Biomedicines Agency
- Patients' survival [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
Patients survival, compared to:
- chronic dialysis HIV patients still listed on the transplantation waiting list - transplanted non-HIV patients using data provide by French Biomedicine Agency
- Phenotyping of lymphocytic infiltrates in case of acute rejection [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]The aim of the immunological phenotyping is to analyse the expression of activation markers between different TCD4 and TCD8 sub-population, this phenotyping will be compared to those observed in acute cell-mediated rejection occurring in the historical cohort of Non-HIV patients. In addition, the rate and expression of Treg population will be evaluated.
- Incidence of AIDS defined diseases and severe morbidity diseases after renal transplantation [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]Severe morbidity diseases include: pathological infections, malignancies, metabolic and cardiovascular diseases.
- Immunological and virologic status after renal transplantation [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]Immunological (lymphocyte activation and inflammatory parameters) and virologic status (kinetics of viral replication: HIV RNA in blood, total HIV DNA in PBMC) monitoring after renal transplantation. These parameters will be compared with pre-transplant status.
- Evaluation of the switch by raltegravir at the time of renal transplantation [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]Assessment of ARV medications change and introduction of raltegravir at the time of renal transplantation in terms of reduction of pharmacokinetic interaction between antiretroviral regimen including raltegravir and immunosupressive treatments. In addition, virological efficacy of antiretroviral treatment including Raltegravir will be evaluated.
- Viral load control after switch by antiretroviral treatment including raltegravir after renal transplantation [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]The aim of this study is to evaluate at the time of renal transplantation the virologic efficiency after the switch by an antiretroviral regimen including Raltegravir in terms of viral load control an virological failure as Raltegravir is known for its low genetic barrier.
- Survival and waiting period of HIV patients registered on French biomedicine agency for renal transplantation [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]Assessment of HIV patients' waiting period until renal transplantation and survival of patients registered on French biomedicine agency waiting-list compared to Non-HIV population (data provided by French Biomedicine Agency )
- Measurement of Area under plasma concentration (AUC) variability of immunosuppressive drugs after introduction of antiretroviral regimen containing Raltegravir [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]Area under plasma concentration (AUC) of Raltegravir and immunosuppressive drugs (Tacrolimus and Mycophenolate Mophetyl) will be measured as well as residual concentration of Tacrolimus. This study is performed in order to verify immunosupressive treatments dosage adaptation.
| Estimated Enrollment: | 50 |
| Study Start Date: | December 2011 |
| Estimated Study Completion Date: | November 2016 |
| Estimated Primary Completion Date: | November 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Raltegravir
Raltegravir associated to an antiretroviral regimen without ritonavir boosted antiprotease
|
Drug: Raltegravir
Introduction of Raltegravir 2 days after renal transplantation within an antiretroviral regimen without ritonavir boosted antiprotease
Other Name: Isentress
|
Detailed Description:
Antiretroviral treatment of HIV-1 Infection might interact with immunosuppressive treatments which increase rejection of renal graft incidence.
In addition HIV infection may be modified together with cardiovascular risk. Patients participating to this study will receive after transplantation antiretroviral regimen including Raltegravir.
Raltegravir treatment does not interact with immunosuppressive drugs and thus seems to be the treatment of choice to be associated with immunosuppressive drugs.
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Registration on the French national renal transplantation waiting list (Biomedicines Agency) for a living or cadaveric donor organ
- HIV-1-infected patients treated by a three-drug ARV regimen
- Immuno-virologic criteria at renal transplantation: undetectable viral load (<50 copies/mL) and CD4 >200/mm3 for at least three months on stable ARV
- Age >18 years and <70 years
- Effective contraception for women
- Written informed consent
- Patient with social security coverage
Exclusion Criteria:
-
Permanent:
- Hepatic cirrhosis
- Serious psychiatric illness history
- EBV or HHV8 lymphoproliferation (lymphoma, systemic Kaposi's sarcoma or multifocal Castleman's disease)
- History of PML
- HTLV-1 seropositivity
- Severe pulmonary or cardiovascular disease with poor short-term vital prognosis
- Patient with AgHBs+
- History of cryptosporidiosis
- History of fungal infection with multi resistant fungi not likely to respond to oral antifungal therapy
- Impossibility or refusal of Raltegravir switch, decision made by doctor or patient
-
Temporary:
- Recent malignancy (between 2 and 5 years according to type)
- HPV-related cervical or anal disease: carcinoma in situ, AIN III, CIN III in remission for less than three years
- Active infection
- HCV infection (PCR-positive)
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01453192
Please refer to this study by its ClinicalTrials.gov identifier: NCT01453192
Locations
| France | |
| Hôpital Pellegrin, Service de Nephrologie, Transplantation Rénale, Dialyse | |
| Bordeaux, France, 33076 | |
| CHU De Caen, Service de Néphrologie Hémodialyse | |
| Caen, France, 14033 | |
| Hôpital Henri Mondor, Service de Néphrologie Transplantation | |
| Créteil, France, 94010 | |
| Hôpital Kremlin Bicêtre, Service de Néphrologie | |
| Kremlin Bicêtre, France, 94275 | |
| CHRU Lille, Service de néphrologie | |
| Lille, France, 59037 | |
| CHU de Nantes, Service de Néphrologie et Immunologie Clinique | |
| Nantes, France, 44093 | |
| Hôpital Pasteur, Service de Néphrologie - Transplantation | |
| Nice, France, 06002 | |
| Hopital Saint Louis, Service de Néphrologie | |
| Paris, France, 75010 | |
| Hôpital Necker, Service de Néphrologie adulte | |
| Paris, France, 75743 | |
| Hôpital TENON, Urgences Néphrologiques et Transplantation Rénale | |
| Paris, France, 75970 | |
| Hôpital civil, Service de Néphrologie et Transplantation | |
| Strasbourg, France, 67091 | |
| Hôpital Foch, Service de Néphrologie Transplantation | |
| Suresnes, France, 92151 | |
| Hôpital Rangueil, Service de Néphrologie, HTA, Dialyse, Transplantation | |
| Toulouse, France, 31059 | |
| Hôpital Bretonneau, Service de Néphrologie | |
| Tours, France, 37044 | |
Sponsors and Collaborators
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Merck Sharp & Dohme Corp.
Investigators
| Principal Investigator: | Philippe GRIMBERT, MD | CHU Henri-Mondor | |
| Study Director: | Dominique COSTAGLIOLA, PHD | INSERM U943 |
More Information
Additional Information:
No publications provided
| Responsible Party: | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) |
| ClinicalTrials.gov Identifier: | NCT01453192 History of Changes |
| Other Study ID Numbers: | 2011-001004-35, ANRS 153 TREVE |
| Study First Received: | October 3, 2011 |
| Last Updated: | October 28, 2014 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):
|
Raltegravir Renal transplantation HIV-1 Acute renal graft rejection |
Additional relevant MeSH terms:
|
Kidney Failure, Chronic Renal Insufficiency Renal Insufficiency, Chronic Kidney Diseases Urologic Diseases |
ClinicalTrials.gov processed this record on March 03, 2015